Evotec AG Achieves Milestone With Cardioxyl Pharmaceuticals - as Compound Enters the Clinic

Published: Oct 01, 2009

HAMBURG, Germany and OXFORD, United Kingdom, Oct. 1, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC), a leading provider in the discovery and development of novel small molecule drugs, today announced that the company has achieved an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, that has successfully moved into clinical testing. This milestone has triggered a success payment from Cardioxyl Pharmaceuticals to Evotec.

Back to news